Urinary Tract Infection Models for Preclinical Research

Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, affecting millions of patients every year. They are a major cause of morbidity, recurrence, and healthcare costs, particularly in women, elderly individuals, and hospitalized patients with catheter-associated UTIs. The growing incidence of multidrug-resistant Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecium poses a serious threat, making the development of new therapeutic approaches an urgent priority.

At Vibiosphen, we provide robust and translational urinary tract infection models in rodents to support the development of novel antibiotics, antifungals, and prophylactic strategies. These models are designed to generate clinically relevant data that help pharmaceutical and biotechnology companies accelerate drug discovery and translational research in the field of urogenital infections.

Background of Urinary Tract Infections

UTIs encompass infections of the bladder (cystitis), kidneys (pyelonephritis), and catheter-associated urinary tract infections. Their global burden is amplified by:
•    The emergence of multidrug-resistant uropathogens
•    The high recurrence rate of UTIs, particularly in women and catheterized patients
•    The limited pipeline of novel antibiotics targeting Gram-negative uropathogens
•    The unmet need for preventive strategies such as vaccines and probiotics

Preclinical urinary tract infection models are therefore essential for evaluating the efficacy, safety, and mode of action of new therapeutic candidates.
 

Rodent Models of Pulmonary Infection

Mouse lineages

•    The primary mouse lineages used in preclinical studies are inbred strains known for their genetic uniformity, which minimizes experimental variability.

    C3H/HeN: Highly susceptible to ascending urinary tract infections and chronic colonization, widely used in UTI research to model recurrent infections and pyelonephritis.
    C57BL/6 mice have a T-helper type 1 (Th1) biased immune response, which is a cellular immune response important for fighting intracellular pathogens and cancer.
    BALB/c mice have a T-helper type 2 (Th2) biased immune response. A Th2 response is a humoral immune response that relies on antibodies and is essential for combatting extracellular parasites.

•    Outbred mice, unlike their inbred counterparts, are maintained in large, randomly bred colonies to maximize genetic variation. This heterogeneity makes each mouse genetically unique.
    Swiss mice, OF1 and CD1
The decision to use an inbred or outbred strain depends on the specific research question. Inbred mice are for when you want to minimize all genetic variables and pinpoint the effect of a single factor. Outbred mice are for when you want to see how a factor affects a genetically varied population.

Rat lineages

•    Inbred strain, meaning they are genetically uniform, and provide a consistent baseline for preclinical studies, which is essential for reproducibility.
    Fischer 344 (F344) rats

•    Outbred rats. They have a wide range of genetic variability, which better represents the genetic diversity found in the human population 
    Sprague Dawley rats 
    Wistar rats

The decision to use an inbred or outbred strain depends on the specific research question. Inbred rats are for when you want to minimize all genetic variables and pinpoint the effect of a single factor. Outbred rats are for when you want to see how a factor affects a genetically varied population.

Routes of Administration

Compounds under evaluation can be administered through several routes to reflect clinical usage and pharmacological profiles:
•    Intra urethral inoculation 
•    Oral gavage 
•    Intraperitoneal route
•    Intravenous route
•    Subcutaneous route
•    Intramuscular route
•    Intranasal route
•    Inhalation / aerosolization route
•    Intratracheal route

Pathogens Studied in Vibiosphen UTI Models

Vibiosphen maintains validated bacterial and fungal strains and can adapt models to client-specific isolates.

Bacterial Uropathogens

•    Escherichia coli (uropathogenic strains, UPEC)
•    Klebsiella pneumoniae
•    And further strains available (please ask for specific pathogens)

Fungal Uropathogens

•    Candida albicans (urogenital candidiasis)
•    And further strains available (please ask for specific pathogens)

These models are particularly valuable for evaluating new antibiotics, antifungals, vaccines, and microbiome-based therapies.
 

Readouts in UTI Models

To ensure robust and translational outcomes, Vibiosphen applies a wide range of validated readouts:
•    Microbiological burden: CFU quantification in urine, bladder, kidneys, and systemic organs
•    Clinical scoring: Weight loss, activity, hydration status, urinary symptoms
•    Histopathology: Evaluation of bladder and kidney tissue for inflammation, epithelial damage, and abscess formation
•    Cytokine and biomarker profiling: Analysis of host immune responses in urine, serum, and tissues
•    Recurrence studies: Monitoring reinfection and chronic colonization, especially with UPEC and C. albicans
•    Imaging approaches (bioluminescence/fluorescence when applicable): Non-invasive infection monitoring

These endpoints can be combined and adapted depending on research objectives, providing comprehensive insights into efficacy and mechanisms of action.

Applications of Vibiosphen’s UTI Models

Our urinary tract infection models are applied in a wide range of preclinical studies:
•    Efficacy testing of antibiotics, antifungals, probiotics, and preventive vaccines
•    Pharmacodynamics (PD) studies to establish optimal dosing
•    Host–pathogen interaction and immune response analysis
•    Recurrence and chronic colonization studies
•    Comparative efficacy studies against standard-of-care therapies

Why Choose Vibiosphen?

•    Proven expertise in bacterial and fungal infection models
•    Flexible and customized study designs tailored to sponsor requirements
•    State-of-the-art BSL2 and BSL3 facilities for resistant uropathogens
•    Strong collaborations with pharmaceutical companies, biotech firms, and academic partners

Vibiosphen combines microbiology expertise with translational science to deliver actionable preclinical data that support innovation in urinary tract infection therapeutics.

Contact Us

If you are developing new treatments or preventive strategies against urinary tract infections, Vibiosphen can help accelerate your research.
Contact us today to discuss your project and explore how our UTI models can support your development strategy.
We will be pleased to provide a customized study design tailored to your objectives.